B2

29. (Amended) The method of claim 28, wherein the cardiovascular disease is selected from the group consisting of hypertension, arrhythmia, and angina.

B3

35. (Twice Amended) The method of claim 27, further comprising administering to the subject a medicament other than the compound in an amount effective to treat a cardiovascular disease.

B4

40. (Amended) The method of claim 35, wherein the medicament is administered in an amount effective to treat angina.

B5

42. (Amended) The method of claim 35, wherein the medicament is administered in an amount effective to treat arrhythmia.

44. (Amended) A kit comprising:

- a package housing a container containing a compound to inhibit calcium channels and a pharmaceutically acceptable carrier, wherein the compound has the general structural formula:

B6



wherein R_1, R_2, R_3, R_4, R_5, R_7, R_8, R_9, and R_{10} independent of one another, are selected from the group consisting of -H, halogen, piperonyl, (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl, (C_1-C_6) alkoxy, -CN, -OR', -SR', -NO_2, -NR'R', amino acid, -C(O)R', -C(S)R', -C(O)OR', -C(S)OR', -C(O)SR, -C(S)SR', -C(O)N(R')$_2$, -C(O)C(O)R', -C(S)C(O)R', -C(O)C(S)R', -C(S)C(S)R', -C(O)C(O)OR', -C(S)C(O)OR', -C(O)C(S)OR', -C(O)C(O)SR', -C(S)C(S)OR', -C(S)C(O)SR', -C(O)C(S)SR', -C(S)C(S)SR', -C(O)C(O)N(R')$_2$, -C(S)C(O)N(R')$_2$, -C(O)C(S)N(R')$_2$, and -C(S)C(S)N(R')$_2$;

wherein R_6 is in the ortho position and is selected from the group consisting of -CO-NH-$(CH_2)_{2\text{-}5}NH_2$, -CO-NH-$(CH_2)_{2\text{-}5}$NH-$(CH_2)_z$-H, -CO-NH$(CH_2)_{2\text{-}5}NR_{15}(CH_2)_z$-H, -CO-R', -CO-OR', -CO-SR', -

$CO\text{-}N(R')_2$, -CO-CO-R', -CO-CS-R', -CO-CO-OR', -CO-CS-OR', -CO-CO-SR', -CO-CS-SR', -CO-CO-$N(R')_2$, $-CO\text{-}CS\text{-}N(R')_2$, $-NH\text{-}CO\text{-}NH\text{-}(CH_2)_{2\text{-}5}NH_2$, $-NH\text{-}CO\text{-}NH\text{-}(CH_2)_{2\text{-}5}NH\text{-}(CH_2)_z\text{-}H$, $-NH\text{-}CO\text{-}NH(CH_2)_{2\text{-}5}NR_{15}(CH_2)_z\text{-}H$, -NH-CO-R', -NH-CO-OR', -NH-CO-SR', $-NH\text{-}CO\text{-}NO_2$, $-NH\text{-}CO\text{-}N(R')_2$, -NH-CO-CO-R', -NH-CO-CS-R', -NH-CO-CO-OR', -NH-CO-CS-OR', -NH-CO-CO-SR', -NH-CO-CS-SR', $-NH\text{-}CO\text{-}CO\text{-}N(R')_2$, and $-NH\text{-}CO\text{-}CS\text{-}N(R')_2$,

wherein each R' is $(CH_2)_z$ -NR"R" and wherein R" is independently selected from the group consisting of $(C_1\text{-}C_6)$ alkyl, $(C_1\text{-}C_6)$ alkenyl, $(C_1\text{-}C_6)$ alkoxy, $(C_1\text{-}C_6)$ alkynyl, $(C_6\text{-}C_{20})$ aryl, $(C_6\text{-}C_{20})$ substituted aryl, $(C_6\text{-}C_{26})$ alkaryl, substituted $(C_6\text{-}C_{26})$ alkaryl, and $(C_5\text{-}C_7)$ heteroaryl wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom, wherein the aryl and alkaryl substituents are each independently selected from the group consisting of hydrogen, halogen, $(C_1\text{-}C_6)$ alkyl, $(C_1\text{-}C_6)$ alkenyl, $(C_1\text{-}C_6)$ alkynyl and trihalomethyl;

wherein *z* is 1-6;

wherein R_{15} is selected from the group consisting of halogen, $(C_1\text{-}C_6)$ alkyl, $(C_1\text{-}C_6)$ alkenyl, $(C_1\text{-}C_6)$ alkynyl, and $(C_1\text{-}C_6)$ alkoxy;

wherein X is a group having the following formula;

$$-(CH_2)_m\text{-}Y\text{-}(CH_2)_n\text{-}$$

wherein Y is selected from the group consisting of S, N, and O;

wherein m and n, independent of one another, are integers of 0-5; and,

- instructions for using the compound to treat a subject having a calcium channel blocking disorder.

45. (Amended) The kit of claim 44, wherein the compound is of the general formula: